Seo, Dong-oh http://orcid.org/0000-0003-0315-4489
Holtzman, David M.
Article History
Received: 19 August 2023
Revised: 13 October 2023
Accepted: 16 October 2023
First Online: 4 January 2024
Competing interests
: D.M.H. is a cofounder of C2N Diagnostics, LLC, and is on the scientific advisory board and/or consults for Genentech, Denali, C2N Diagnostics, Cajal Neurosciences, and Asteroid. D.M.H. is an inventor on a patent licensed by Washington University to NextCure on the therapeutic use of anti-apoE antibodies. The Holtzman laboratory receives research grants from the National Institutes of Health, the Cure Alzheimer’s Fund, the Rainwater Foundation, the JPB Foundation, the Good Ventures Foundation, the GHR Foundation, Novartis, Eli Lilly, and NextCure. The authors declare no other competing interests.